Answer
Aug 14, 2025 - 12:11 PM
The duration for which people stay on BRUKINSA (zanubrutinib) can vary significantly based on the individual's response to treatment, the type and stage of the cancer being treated, and the presence of any side effects. Clinical trials and real-world studies often provide specific median durations of treatment, but these can differ depending on the condition being treated, such as chronic lymphocytic leukemia (CLL) or mantle cell lymphoma (MCL). It's essential for patients to follow their healthcare provider's guidance regarding the duration of treatment.
